zonisamide has been researched along with Abnormal Movements in 5 studies
Zonisamide: A benzisoxazole and sulfonamide derivative that acts as a CALCIUM CHANNEL blocker. It is used primarily as an adjunctive antiepileptic agent for the treatment of PARTIAL SEIZURES, with or without secondary generalization.
zonisamide : A 1,2-benzoxazole compound having a sulfamoylmethyl substituent at the 3-position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "On the basis of six randomized controlled trials, zonisamide (ZNS) can be prescribed as add-on treatment in focal adulthood epilepsy in USA and Europe." | 4.85 | [Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases]. ( Janszky, J, 2009) |
| "Dyskinesia was evaluated using Unified Parkinson's Disease Rating Scale (UPDRS) part 4 items 32 (4-32; duration of dyskinesia) and 33 (4-33; disability of dyskinesia) score." | 3.01 | Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials. ( Maruyama, H; Matsumoto, Y; Nakamura, M; Tsuboi, Y, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 4 (80.00) | 2.80 |
| Authors | Studies |
|---|---|
| Tsuboi, Y | 2 |
| Nakamura, M | 1 |
| Maruyama, H | 1 |
| Matsumoto, Y | 1 |
| Jing, XZ | 1 |
| Yuan, XZ | 1 |
| Luo, X | 1 |
| Zhang, SY | 1 |
| Wang, XP | 1 |
| Mishima, T | 1 |
| Chiu, SW | 1 |
| Saiki, H | 1 |
| Yamaguchi, T | 1 |
| Shimo, Y | 1 |
| Maeda, T | 1 |
| Watanabe, H | 1 |
| Kashihara, K | 1 |
| Nomoto, M | 1 |
| Hattori, N | 1 |
| Murata, M | 1 |
| Odawara, T | 1 |
| Hasegawa, K | 1 |
| Kajiwara, R | 1 |
| Takeuchi, H | 1 |
| Tagawa, M | 1 |
| Kosaka, K | 1 |
| Janszky, J | 1 |
2 reviews available for zonisamide and Abnormal Movements
| Article | Year |
|---|---|
An Update on Nondopaminergic Treatments for Motor and Non-motor Symptoms of Parkinson's Disease.
Topics: Antiparkinson Agents; Dopamine; Dyskinesias; Humans; Levodopa; Parkinson Disease; Serotonin; Zonisam | 2023 |
[Role of zonisamid in treating epilepsy, Parkinson disorders and other neurological diseases].
Topics: Anticonvulsants; Bipolar Disorder; Calcium Channels, T-Type; Cholinergic Agents; Dopamine Agents; Dy | 2009 |
2 trials available for zonisamide and Abnormal Movements
| Article | Year |
|---|---|
Zonisamide improves wearing off in Parkinson's disease without exacerbating dyskinesia: Post hoc analysis of phase 2 and phase 3 clinical trials.
Topics: Antiparkinson Agents; Double-Blind Method; Dyskinesias; Humans; Levodopa; Parkinson Disease; Zonisam | 2021 |
Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial.
Topics: Aged; Aged, 80 and over; Calcium Channel Blockers; Double-Blind Method; Dyskinesias; Female; Humans; | 2020 |
1 other study available for zonisamide and Abnormal Movements
| Article | Year |
|---|---|
Risk factors for developing dyskinesia among Parkinson's disease patients with wearing-off: J-FIRST.
Topics: Antiparkinson Agents; Catechol O-Methyltransferase; Dopamine Agonists; Dyskinesias; Female; Humans; | 2023 |